[
  {
    "ts": null,
    "headline": "Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules",
    "summary": "NEW YORK (Reuters) -A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.  U.S. District Judge Victor Marrero in Manhattan said Wyeth, a drugmaker Pfizer bought in 2009, did not qualify as a victim of the securities violations underlying the SEC case, and therefore was not entitled to the funds.",
    "url": "https://finnhub.io/api/news?id=355291dfd3f79517093d2a26733b957a650db64a4ba9ee2128753b1bc4e1ef88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732053936,
      "headline": "Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules",
      "id": 131495826,
      "image": "https://media.zenfs.com/en/reuters.com/50cb3e12383fd8492396e705bad62321",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK (Reuters) -A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.  U.S. District Judge Victor Marrero in Manhattan said Wyeth, a drugmaker Pfizer bought in 2009, did not qualify as a victim of the securities violations underlying the SEC case, and therefore was not entitled to the funds.",
      "url": "https://finnhub.io/api/news?id=355291dfd3f79517093d2a26733b957a650db64a4ba9ee2128753b1bc4e1ef88"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market",
    "summary": "On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene. Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease The OL",
    "url": "https://finnhub.io/api/news?id=fa07e63b8df5619ac7ad3c95c0a0bad157c8fda9b860d953009403a088b0094f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732045499,
      "headline": "BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market",
      "id": 131492429,
      "image": "https://media.zenfs.com/en/Benzinga/8bfd3961a9ce4af52518bf5287ba639a",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene. Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease The OL",
      "url": "https://finnhub.io/api/news?id=fa07e63b8df5619ac7ad3c95c0a0bad157c8fda9b860d953009403a088b0094f"
    }
  },
  {
    "ts": null,
    "headline": "If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%",
    "summary": "I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Click here to read why.",
    "url": "https://finnhub.io/api/news?id=2c27f76c1a4473b68a35deb23938849d0cdc0e57de84b554bb3fc7a67d64297d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732039200,
      "headline": "If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%",
      "id": 131493816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160839858/image_1160839858.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Click here to read why.",
      "url": "https://finnhub.io/api/news?id=2c27f76c1a4473b68a35deb23938849d0cdc0e57de84b554bb3fc7a67d64297d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer loses bid to recoup $75 million left over from SEC settlement",
    "summary": "A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC...",
    "url": "https://finnhub.io/api/news?id=7cf78871a372d739a881baddda8f2faf2d95847765a903f1776853053c7727cd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732035936,
      "headline": "Pfizer loses bid to recoup $75 million left over from SEC settlement",
      "id": 131492674,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC...",
      "url": "https://finnhub.io/api/news?id=7cf78871a372d739a881baddda8f2faf2d95847765a903f1776853053c7727cd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1b3cdfb1bddbe2e43b7a38a6fe65786f9d7dcd370fdecbd6215c63bb32f10a73",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732034400,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 131508365,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1b3cdfb1bddbe2e43b7a38a6fe65786f9d7dcd370fdecbd6215c63bb32f10a73"
    }
  },
  {
    "ts": null,
    "headline": "ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs",
    "summary": "Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.",
    "url": "https://finnhub.io/api/news?id=fcf08aa7683e5b1f03676240c2c6e5455204f82d682341b50d2e9e1b23368a63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732025940,
      "headline": "ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs",
      "id": 131480785,
      "image": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.",
      "url": "https://finnhub.io/api/news?id=fcf08aa7683e5b1f03676240c2c6e5455204f82d682341b50d2e9e1b23368a63"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) stock falls 5.3% in past week as three-year earnings and shareholder returns continue downward trend",
    "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...",
    "url": "https://finnhub.io/api/news?id=4889c9df5a82b7a68e1cf82306b41b6fece46f6986199f2be455020714010283",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732024833,
      "headline": "Pfizer (NYSE:PFE) stock falls 5.3% in past week as three-year earnings and shareholder returns continue downward trend",
      "id": 131485843,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...",
      "url": "https://finnhub.io/api/news?id=4889c9df5a82b7a68e1cf82306b41b6fece46f6986199f2be455020714010283"
    }
  },
  {
    "ts": null,
    "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
    "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
    "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732021874,
      "headline": "Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)",
      "id": 131480822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "SPDRÂ® S&P Biotech ETF had its worst week since 2020, but the sector remains undervalued. Read why XBI is a strong buy for patient investors.",
      "url": "https://finnhub.io/api/news?id=109ddd120641122e255332ba00679b7b978c2e03ced531275de667fe4d7d4cd2"
    }
  },
  {
    "ts": null,
    "headline": "These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth",
    "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, SMP, GBX and PFE hold promise.",
    "url": "https://finnhub.io/api/news?id=9d8147d006037ae87afc275c9a8357a346f2bf8838d65f1a5819714a090d6e8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732020060,
      "headline": "These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth",
      "id": 131485309,
      "image": "https://media.zenfs.com/en/zacks.com/124f1f4e4fcc578e5486ea52e0d08740",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, SMP, GBX and PFE hold promise.",
      "url": "https://finnhub.io/api/news?id=9d8147d006037ae87afc275c9a8357a346f2bf8838d65f1a5819714a090d6e8c"
    }
  },
  {
    "ts": null,
    "headline": "How I Repurposed My Late Father's Trust Account",
    "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
    "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732019685,
      "headline": "How I Repurposed My Late Father's Trust Account",
      "id": 131478623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175431947/image_175431947.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
      "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
    "summary": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
    "url": "https://finnhub.io/api/news?id=86f1072bb8ddf5880fad8de189b79a3d5ef21744dc3348ce38e64d7ac8e4a46e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732017420,
      "headline": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
      "id": 131508366,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "BioNTech Stock Has Been Hit Hard Since RFK Jr.’s Nomination. Why This Analyst Upgraded It.",
      "url": "https://finnhub.io/api/news?id=86f1072bb8ddf5880fad8de189b79a3d5ef21744dc3348ce38e64d7ac8e4a46e"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
    "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015683,
      "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
      "id": 131474886,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429734/image_107429734.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
      "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12"
    }
  },
  {
    "ts": null,
    "headline": "October Readers Tagged 25 Ideal Dividend Dogs Including 6 'Safer' Of 39 Picks",
    "summary": "25 out of 39 ReFa/Ro dogs are \"ideal\" investments. Read why dividends from $1k investment often exceed share prices, with 6 also marked as \"safe.\"",
    "url": "https://finnhub.io/api/news?id=83ac8c358c99582135f61bc72cd789a314d81ba435964fcccdd9ae368d954ded",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732012034,
      "headline": "October Readers Tagged 25 Ideal Dividend Dogs Including 6 'Safer' Of 39 Picks",
      "id": 131471945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/489013560/image_489013560.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "25 out of 39 ReFa/Ro dogs are \"ideal\" investments. Read why dividends from $1k investment often exceed share prices, with 6 also marked as \"safe.\"",
      "url": "https://finnhub.io/api/news?id=83ac8c358c99582135f61bc72cd789a314d81ba435964fcccdd9ae368d954ded"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Newmont, Uber, Adobe and Qualcomm",
    "summary": "Pfizer, Newmont, Uber, Adobe and Qualcomm are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=4eb2f5579e4bdd392503132879135ea033520db29080ee9683408061b6904cd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732010400,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Newmont, Uber, Adobe and Qualcomm",
      "id": 131469523,
      "image": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer, Newmont, Uber, Adobe and Qualcomm are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=4eb2f5579e4bdd392503132879135ea033520db29080ee9683408061b6904cd4"
    }
  }
]